2026-04-14T02:20:24Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/137972025-10-24T10:29:41Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
De Martin, Eleonora
author
Riveiro-Barciela, Mar
2025-10-24T10:29:41Z
2025-10-24T10:29:41Z
2025-10-06T12:54:03Z2025-10-06T12:54:03Z2025-09
http://hdl.handle.net/11351/13797
Antibody-drug conjugates; Checkpoint inhibitors; HepatotoxicityConjugados anticuerpo-fármaco; Inhibidores de puntos de control; HepatotoxicidadConjugats d'anticossos-fàrmacs; Inhibidors de punts de control; HepatotoxicitatThe advent of novel oncological therapies, including immune checkpoint inhibitors, antibody-drug conjugates, and protein kinase inhibitors, has revolutionised cancer treatment by significantly improving patient survival across a range of malignancies. However, these advances have been accompanied by the emergence of new and often unpredictable adverse events, among which hepatotoxicity represents a growing clinical challenge. In this review, we provide a comprehensive synthesis of current knowledge on liver injury associated with these three key classes of oncological agents, with a particular focus on mechanisms of action and hepatotoxicity, clinical presentation, and management strategies. Given the expanding use of these agents, both as monotherapies or in combination regimens, this topic is of pressing relevance to hepatologists and oncologists alike. As combination therapies become increasingly common, the complexity of drug-liver interactions and their implications for patient safety demand greater interdisciplinary awareness and collaboration. This review advocates for a pragmatic approach to the management of drug-induced liver injury in patients with cancer, underscoring the critical need to balance hepatic preservation with the imperative of maintaining oncological efficacy in this uniquely vulnerable population. By addressing an emerging area of clinical importance, we aim to stimulate further research on oncological hepatotoxicity, a phenomenon that is poised to become increasingly prevalent in routine clinical practice.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Hepatotoxicitat
Fetge - Malalties - Tractament
Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris
Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris
Immunoglobulines - Ús terapèutic - Efectes secundaris
DISEASES::Chemically-Induced Disorders::Chemically-Induced Disorders::Poisoning::Chemical and Drug Induced Liver Injury
DISEASES::Digestive System Diseases::Liver Diseases
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates
Other subheadings::Other subheadings::Other subheadings::/adverse effects
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::trastornos inducidos químicamente::trastornos inducidos químicamente::intoxicación::trastornos hepáticos provocados por fármacos y productos químicos
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
Navigating liver toxicity in the age of novel oncological agents
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion